Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Public ClinicalTrials.gov record NCT04550494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
Study identification
- NCT ID
- NCT04550494
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 36 participants
Conditions and interventions
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Castration-Resistant Prostate Carcinoma
- Clinical Stage III Gastric Cancer AJCC v8
- Clinical Stage IV Gastric Cancer AJCC v8
- HER2-Positive Breast Carcinoma
- Locally Advanced Breast Carcinoma
- Locally Advanced Gastric Carcinoma
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced Ovarian Carcinoma
- Locally Advanced Pancreatic Carcinoma
- Locally Advanced Prostate Carcinoma
- Metastatic Breast Carcinoma
- Metastatic Gastric Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Ovarian Carcinoma
- Metastatic Pancreatic Carcinoma
- Metastatic Prostate Carcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Recurrent Breast Carcinoma
- Recurrent Gastric Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Pancreatic Carcinoma
- Recurrent Prostate Carcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
Interventions
- Biopsy Procedure Procedure
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
- Talazoparib Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2021
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Apr 12, 2026
2021 – 2026
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UF Health Cancer Institute - Gainesville | Gainesville | Florida | 32610 | Recruiting |
| National Cancer Institute Developmental Therapeutics Clinic | Bethesda | Maryland | 20892 | Recruiting |
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | Active, not recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04550494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04550494 live on ClinicalTrials.gov.